PMC58 THE POTENTIAL PENALTY FOR NOT SAMPLING FROM THE RISK SET IN NESTED CASE-CONTROL DESIGNS: EVIDENCE FROM SIMULATED DATA  by Kiri, VA & Feudjo-Tepie, M
volumes and costs. Correlations and paired T-tests were used to
compare simulated annual costs with actual annual costs from
the continuous measurements. RESULTS: Analyses conﬁrmed
that discontinuous measurements using cost diaries offer good
estimates of annual health expenditures, but measurement pat-
terns and imputation methods did inﬂuence the outcomes, as the
correlations differed between methods. The best estimated
annual costs were obtained by random cohort measurement,
using three random cohorts, ensuring that at least a third of the
participants were measuring costs each month, combined with
IM imputation. Discontinuous measurement of health expendi-
tures carries a small risk of missing infrequent expensive events,
which may result in underestimation of annual costs. CONCLU-
SIONS: To reduce the burden on participants in future economic
evaluation, we recommend calculating annual costs from discon-
tinuous measurements in random cohorts, combined with IM
imputation.
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OBJECTIVES: Appropriate design and efﬁcient analytical strat-
egy are generally considered as some of the prerequisites for a
valid and reliable health outcomes research on non-randomized
observational data. For rare outcomes, the case-control design is
often presented as the most efﬁcient, whereby, proper selection of
controls is crucial. Using simulated data for the nested case-
control design, we assess the relative efﬁciencies of two sampling
strategies for the controls- the version where controls can never
be cases (design 1) and the recommended approach in which
controls are sampled from the risk sets such that some controls
can be future cases (design 2). METHODS: In each simulation,
we assumed an underlying hazard that follows a Weibull distri-
bution with inputted values for the scale and shape parameters to
generate 100 sets of cohorts of 4000 patients in treatment groups
(i.e. treated and untreated). The process also involved an
assumed hazard ratio for treatment and 3 factors that required
adjustments. Designs 1 and 2 were then applied successively on
each of the resulting datasets and then analysed to obtained for
each design, the estimated odds ratio (OR- an approximate of the
inputted hazard ratio) and its 1st and 3rd quartiles. RESULTS: We
considered over 50 scenarios for hazard ratio that varied between
0.3 and 4.0. The absolute differences between the inputted
hazard ratio and the estimated odd ratio ranged from 0.01–8.00
and from 0.01–0.50 for designs 1 and 2 respectively. The input-
ted hazard ratio was within the inter-quartile range of the OR in
less than 5% of the runs with design 1 but more than 80% with
design 2. CONCLUSIONS: Our study suggests that in nested
case-control designed studies, if controls are not sampled from
the appropriate risk sets, we can expect much larger bias in our
estimates than with correct sampling.
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OBJECTIVES: Economic analyses in health technology assess-
ment often require estimation of absolute risk difference (ARD)
for outcomes such as survival or progression, given base risk in
the jurisdiction of interest and trial evidence of treatment effects.
We demonstrate that odds ratios (OR) provide distinct advan-
tages over relative risk (RR) in consistently estimating such ARD
independent of the framing of effects (e.g. mortality or survival)
for direct and indirect comparisons. METHODS: Use of RR is
shown to lead to inferential anomalies in estimating ARD, while
consistently estimated using OR. These inferential anomalies and
odds solution are illustrated for indirect comparison of Natiluz-
imab versus Interferon beta-1b for multiple sclerosis, as well as
direct comparisons. RESULTS: Standard use of relative risk to
calculate ARD in indirect comparison suggests Natiluzimab is
more effective than Interferon for progression (RR = 0.70, ARD
= 21% for a base risk of 70% progression) but less effective than
Interferon for no progression (RR = 0.84, ARD = 4.8%). This
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